ECLECTIC: 18 F-fluoroestradiol PET and Circulating Biomarkers to Guide the Choice of the Second Line Therapy for ER+, HER2- Metastatic Breast Cancer: A Phase 3 Trial.
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined